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Purpose: To assess whether HPV 16 originally detected in adolescent women can be redetected in adulthood.
Methods: A convenience sample of 27 adult women with known HPV 16 detection during adolescence was
assessed for HPV 16 redetection. A comparison of the long control region (LCR) DNA sequences was performed
on some of the original and redetected HPV 16 isolates.
Results: Median age at reenrollment was 27.5 years (interquartile range of 26.7–29.6). Reenrollment occurred
six years on average after the original HPV 16 detection. Eleven of 27 women had HPV 16 redetected. Some of
these HPV 16 infections had apparently cleared during adolescence. LCR sequencing was successful in paired
isolates from 6 women; in 5 of 6 cases the redetected HPV 16 isolates were identical to those detected during
adolescence,
Conclusions: HPV 16 may be episodically detected in young women, even over long time periods. HPV 16 re-
detection with identical LCR sequences suggests low-level persistent infection rather than true clearance, al-
though newly acquired infection with an identical HPV 16 isolate cannot be excluded. However, this study
suggests that a new HPV 16-positive test in a clinical setting may not indicate a new infection.
1. Introduction
Despite the high prevalence of HPV infection in women, only a
small percentage of these infections lead to cervical dysplasia or cancer.
Most become undetectable within 12 months of the initial HPV detec-
tion, a phenomenon commonly referred to as clearance [1,2]. However,
in studies with longitudinal follow-up periods up to six years, episodic
detection of oncogenic HPV (with long time periods of apparent
clearance) has been regularly demonstrated in young women [3–6].
Although HPV 16 can be detected in the months or even years im-
mediately prior to the diagnosis of cervical cancer, it is unclear is this
represents episodic detection of a previously acquired infection (low-
level persistence) or a new HPV 16 infection [8]. HPV, a DNA virus,
uses the host cell machinery to replicate. The rate of mutation of HPV
mirrors that of the human genome, and is stable over time with some
estimating an evolutionary rate of only one magnitude greater than that
of their human hosts [9]. Of the nine regions of the HPV 16 genome, the
long control region is the most variable of all of the genome regions
[10]. The sequence variability in this region may be as high as 5%
among HPV 16 isolates and has been used to follow transmission of
HPV 16 isolates among cohorts and to understand persistent HPV 16
infections [11,12].
Various models have been proposed to explain detection patterns of
HPV after apparent clearance, but the clinical relevance of these pat-
terns of detection are not well understood [13–15]. In certain devel-
oped countries, primary cervical cancer screening with HPV DNA fol-
lowed by type determination will replace cytological screening in
upcoming years. Episodically detected high-risk HPV (HR-HPV), in-
cluding HPV 16, therefore has implications in this new method of
screening. In addition, the attributable risks of episodically detected
infections vs. incident infections acquired later in life are not known but
may diﬀer.
To test the hypothesis that some HPV redetection episodes may be
due to reactivation of a previously acquired infection, we reenrolled 30
women from a longitudinal cohort study known as the Young Women's
Project (YWP) [16]. During the YWP, these women were tested
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quarterly for HPV using self-collected vaginal swabs and annual cer-
vical sampling. At reenrollment (the current study) data was gathered
to assess whether 1) women with prior HPV 16 detection continued to
have HPV 16 detected after a decade or longer, and 2) if the original
and redetected HPV 16 isolates were identical or nearly identical
(suggesting reactivation) or diﬀerent (suggesting reinfection).
2. Material and methods
2.1. Study population and design
The current study was approved by the Institutional Review Board
at Indiana University School of Medicine. Consent for re-contact of
women enrolled in a prior study (the YWP) was already in place;
however, all participants were consented again at enrollment for this
study. We preferentially contacted women who had HPV 16 and or HPV
18 detected during their YWP observation [16–18]. Women in the YWP
study (1998 through 2007) were contacted consecutively based on date
of study enrollment, beginning with the earliest enrollment, and the
ﬁrst 30 to agree to participate verbally and present for their scheduled
appointment constituted the study sample. A convenience sample of 30
women was re-enrolled. For 3 women who were reenrolled, no record
of HPV 16 detection was found during their YWP observation, so these
3 women were excluded in this analysis that focused on HPV 16 re-
detection.
Two study visits were required. At Visit 1, women were interviewed
for intervening sexual histories and behaviors (from last date of YWP
observation to current enrollment) as well as lifetime histories of pre-
vious and abnormal cervical cytological testing (Pap smear) and
treatment for such abnormalities. After the interview, cervical swabs
were collected for HPV testing and sequencing as described below, and
a Pap smear was obtained. At Visit 2, participants provided a self-ob-
tained vaginal swab for HPV testing. Pap smear and HPV results from
Visit 1 were discussed with participants. The median time between Visit
1 and 2 for all participants was 33 days (IQR 22.5–54.5). Arrangements
for follow-up with primary providers were made if the Pap smear was
abnormal or if the participant's swab was positive for HPV types 16 or
18.
2.2. HPV testing
DNA was extracted from cervical or vaginal swabbed specimens as
previously described [19]. The Linear Array HPV Genotyping test
(Roche Molecular Diagnostics, Indianapolis, Indiana) (LA-HPV) was
used for HPV detection and genotyping. This assay detects 37 HPV
types using 5′ biotin-labeled primer pools for polymerase chain reaction
(PCR) ampliﬁcation within the L1 region of the HPV genome. Reactions
were ampliﬁed in an Eppendorf Mastercycler® proS using the same
parameters as previously described [20]. A positive control reaction
(sample provided by Roche Molecular Diagnostics) and negative con-
trol reaction (no DNA) were performed with each assay. The GH20/
PC04 human β-globin target was co-ampliﬁed to determine sample
adequacy. Determination of speciﬁc HPV types was performed using
the Roche Linear Assay (Roche Diagnostics, Indianapolis, Indiana) as
previously described [19,21]. A semi-quantitative scoring system was
used to estimate HPV viral load in samples from adolescent as pre-
viously described [22]. The low positive beta-globin band was assigned
a value of 2, and the high positive band was assigned a value of 5. The
intensity of HPV 16 bands on assay strips (“signal strength”) was
compared to the low and high beta-globin bands and scored relative to
these bands and given a score of 1–5.
2.3. Sequencing of the LCR region
The long control region (LCR) is the most variable region within the
HPV genome with as much as 5% variability within variants, and has
been used to characterize HPV isolates of various types [23–25]. When
a participant tested positive for HPV 16 at one of the two study visits, a
paired sampled was identiﬁed for comparison of LCR sequence. The
paired sample consisted of the last HPV 16-positive swab during their
YWP observation and an HPV 16-positive swab identiﬁed at re-enroll-
ment. If ampliﬁcation from the last positive swab during their YWP was
unsuccessful, the next closest collected HPV 16-positive swab from that
participant's longitudinal testing was used.
For sequencing, three overlapping primer pairs were developed
such that the entire LCR was ampliﬁed (Table 1). The overlapping
primer design was used to reduce error per sequencing reaction and
increase sensitivity of the ampliﬁcation [26]. The HPV 16 sequence
used to determine the nucleotide number is located in GenBank under
the accession number K02718.1. The percent homology between HPV
16 isolates was calculated by dividing the number of nucleotide non-
identities by the total number of nucleotides sequenced, multiplied by
100. If sequencing for the identiﬁed pairs of HPV was more than 98%
homologous, the pair was considered identical. As all of the participants
were from a geographically limited area, determining the intertype
variants may not have provided suﬃcient sequence variation to dif-
ferentiate two isolates within the same type. de Villiers, et al. has noted
a 2 to 5% variabilityin the LCR among HPV isolates of the same type
[9]. Therefore, we selected this highly variable region for sequencing,
and a cut-oﬀ of≤2% diﬀerence in this region was used to diﬀerentiate
HPV 16 isolates.
Five microliters of extracted DNA from each sample were used for
ampliﬁcation of the LCR region. PCR reactions were carried out using
5 µL of each primer (0.5 µM ﬁnal concentration), 25 µL of Roche
FastStart™ Master Mix (Roche Diagnostics), 10 µL of water on an
Eppendorf Mastercycler® pro S for a ﬁnal reaction volume of 50 µL.
Reaction parameters were as follows: 94 °C for 9min, 94 °C for 30 s,
56 °C for 30 s, 72 °C for 45 s all for 40 cycles followed by 72 °C for 7min
for the ﬁnal extension step.
Ampliﬁcation products were visualized on an agarose gel and the
products corresponding to the expected size were excised and puriﬁed
using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany).
Puriﬁed LCR segments were sequenced using BIgDye terminator version
3.1 on an ABI 3730 XL instrument by ACGT, Inc. (Wheeling, IL). The
sequences of the overlapping segments from the same sample were
aligned using Basic Local Alignment Search Tool (BLAST) available on
the NCBI website to create the full LCR sequence for that sample. The
complete LCR sequence from one sample collected during the original
YWP observation was then aligned with a sample from the re-enroll-
ment period using BLAST.
Table 1
Long Control Region (LCR) sequencing primers, nucleotide coordinates, and exact sequences.
HPV 16 LCR segment Nucleotide coordinates spanning the segment Primer sequence
Segment 1 Forward 7288-7626 5′-TGCTTGTGTAACTATTGTGTC-3′
Segment 1 Reverse 5′-GTTGCACATAGTGCAGTGTAA-3′
Segment 2 Forward 7498-7788 5′-AGTTCTATGTCAGCAACTATGG-3′
Segment 2 Reverse 5′-AACTAGGGTGACATTTAGTTGG-3′
Segment 3 Forward 7681-115 5′-CCTTACATACCGCTGTTAGG−3′
Segment 3 Reverse 5′-GTCCTGAAACATTGCAGTTCT−3′
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2.4. Statistical analyses
Descriptive analysis (mean, standard deviation, median, inter-
quartile range [IQR]) of the study population, HPV 16 detection, and
Pap smears were conducted and reported. Two terms were used in the
YWP study to describe HPV events for analysis and epidemiology of
HPV infections [3]. First, if an HPV 16 infection had not been detected
for the last two observation points in the YWP (at the end of the study
observation), the infection was said to have “cleared”. If an HPV in-
fection was detected, then followed a period of non-detection of greater
than or equal to six months (2 or more consecutive quarterly visits),
then redetected, the term “episodic detection” was applied. The ana-
lysis of HR-HPV types was restricted to the 13 types considered Group 1
carcinogens (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66) [27].
3. Results
3.1. Characteristics of participants
Twenty-seven women were re-enrolled with HPV 16 detected
during their YWP observation period. The median age at YWP enroll-
ment was (interquartile range) 15.9 years (IQR 14.9–16.7), and the
median age at the time of re-enrollment into the current study was 27.5
years (IQR 26.7–29.6). The median time between participant's ﬁnal
YWP visit and re-enrollment was 5.9 years (IQR 5.5–6.4). The majority
of women identiﬁed themselves as African-American or Black (N = 24,
or 88%). The comparison of the cohort characteristics from the YWP (N
= 147) and the re-enrolled cohort are shown in Table 2. There were no
signiﬁcant diﬀerences found between the larger YWP cohort and the
subset of 27 women who were re-enrolled.
3.2. HPV 16 infection and redetection
HPV 16 was detected during the YWP for an average of 2.58 years
(SD = 2.46) for this group of 27 women. Eleven of 27 (40.7%) had HPV
16 detected again in the reenrollment study. For these 11 women, the
mean time between the last detected HPV 16 in the YWP until re-
detection was 8.5 years (SD = 3.3) with a median (interquartile range)
of 7.1 (5.6–11.2). The median time between visit 1 and visit 2 was 33.0
days (IQR 22.5–54.5).
Examining the patterns of HPV 16 detection during the YWP ob-
servation period, 6 of the 11 women with HPV 16 redetections had
“cleared” their infections (minimally having the last two observation
points negative for the HPV type) while 5 met the study deﬁnition for
ongoing infection or were “right censored” (HPV 16 detected in one or
both of the last two points of observation in the YWP). For those women
who had “cleared” their HPV 16 infection, the mean time from last HPV
16 detection was 10.7 years versus 5.7 years for those participants
whose HPV 16 infection was “right censored” (t = 4.45, p = .005). The
status of HPV 16 detection for all 27 women with HPV 16 infection
during and at the last observation period in the YWP is shown in
Table 3. Among the eleven women with redetection of HPV 16, HPV
was detected only in the cervical swab in 8 women, and in the vaginal
swab in 3 women. None of the 11 women had HPV 16 detected in both
cervical and vaginal swabs (Table 3).
3.3. Pap smears
Pap smear results among 27 women included 23 normal smears and
4 with low-grade changes (2 ASCUS and 2 LGSIL) (Table 4). Twenty-
two of these 27 women reported a history of previously abnormal Pap
tests. Three women had documented histories of treatment for cytolo-
gical abnormalities including one woman who underwent cold knife
conization.
Table 2
Comparison of the cohort characteristics between the YWP and those participants who
were re-enrolled.
Characteristic YWP, mean
(SD)
Reenrolled, mean (SD) p-value
N = 147 N = 27
Age at enrollment (years) 15.41 (1.04) 15.27 (1.08) 0.52a
Age at ﬁrst sex (years) 14.4 (1.7) 14.2 (1.4) 0.72a
Duration of follow-up
(years)
5.79 (1.5) 6.05 (1.8) 0.51c
Number of partnersd
Enrollment 2.92 (3.50) 3.33 (4.57) 0.10c
Last Visit 10.6 (6.8) 12.6 (6.3) 0.13c
YWP, N (%) Reenrolled N, (%)
N = 147 N = 27
Race
African American 139 (94.6) 26 (96.3) 0.10b
White 8 (5.4) 1 (3.7)
Sexual Experience
At enrollment 125 (85.0) 25 (92.6) 0.38b
By the last visit 146 (99.3) 27 (100) 0.10b
History of STI**
At enrollment 26 (17.7) 4 (14.8) 0.10b
By the last visit 125 (85.0) 25 (92.6) 0.38b
YWP women (n = 147) includes 146 women from HPV project & 1 woman from original
YWP project.
Reenrolled women (n = 27) includes 26 women from HPV project & 1 woman from
original YWP project.
Time point of acquisition of data is dependent upon the characteristic mentioned.
†STI = cumulative number of sexually transmitted infections other than human pa-
pillomavirus at enrollment and at the last visit. These include Chlamydia trachomatis,
Neisseria gonorrhoeae, and Trichomonas vaginalis.
a t-test.
b Fisher's Exam test.
c Wilcoxon sum rank test.
d Mean number of unique cumulative lifetime partners within 2 months of enrollment
and at the end of the study.
Table 3
HPV 16 detection based on collection method for each visit in the reenrollment study by
study subject.
Participant
number
Cervical
swab HPV
16
Self-
collected
HPV 16
HPV 16
Redetection
from YWP
Status of HPV
16 detection
at the end of
YWP†Visit 1
(Score)*
Visit 2
(Score)*
1 1 – ‡ Censored
2 – 2 ‡ Censored
3 – 1 ‡ Censored
4 – 1 ‡ Censored
5 1 – ‡ Censored
6 2 – ‡ Cleared
7 1 – ‡ Cleared
8 5 – ‡ Cleared
9 1 – ‡ Cleared
10 1 – ‡ Cleared
11 3 – ‡ Cleared
12 – – Censored
13 – – Censored
14 – – Censored
15 – – Censored
16 – – Censored
17 – – Cleared
18 – – Cleared
19 – – Cleared
20 – – Cleared
21 – – Cleared
22 – – Cleared
23 – – Cleared
24 – – Cleared
25 – – Cleared
26 – – Cleared
27 – – Cleared
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3.4. Analysis of LCR sequencing of HPV 16 isolates
Of the eleven HPV 16 isolates that were redetected during the re-
enrollment study, six were successfully ampliﬁed in all three segments
for both the original and redetected isolates. The mean number of nu-
cleotides sequenced for these 6 isolates was 747 base pairs with a range
of 744–752. The median number of non-identities identiﬁed between
HPV 16 isolates from the original observational period and the re-en-
rollment period was 9 1–15 nucleotides), and all non-identities were
single nucleotide changes. The number of nucleotides sequenced,
number of non-identities, and percent similarity between the HPV 16
isolates from the ﬁrst observation period and the reenrollment period
are shown in Table 5. The mean percentage of non-identities was 1.1%
(range 0.1–2.0%), and the percentage of non-identities was less than
2.0% in isolates from all but one participant. There were no deletions or
insertions found within the LCR segments between HPV 16 isolates
from the original observational period and the re-recruitment period.
For the woman whose HPV 16 isolates were 2% diﬀerent, the band
intensity corresponding to this result from the YWP specimen was 5 +
and for the reenrollment specimen was 3 +, indicating a high viral load
or a large number of HPV 16-infected cells in the specimen.
For 5 of 11 women with HPV 16 redetection, either the original
isolate from the YWP or the HPV 16 isolate from the reenrollment study
could not be ampliﬁed suﬃciently (i.e., one of the three segments failed
multiple attempts at ampliﬁcation) for sequencing and therefore could
not be included in the comparison.
4. Discussion
Many women are infected with HPV 16 and other oncogenic types
in the ﬁrst years after sexual debut. In most cases, type-speciﬁc HPV
DNA can be detected by PCR for a few months after the initial detec-
tion, then the infection “clears”, meaning that the type-speciﬁc HPV
DNA is no longer detected in one or two subsequent specimens.
Whether the HPV has been truly eradicated has not been established.
However, it is possible that a few infected cells remain in basal layers of
epithelium in women with cleared infections, but the specimen contains
only a few actual copies of HPV 16, below the level of detection of the
PCR assay.
In the current study, 27 closely followed women with HPV 16 in-
fections detected during adolescence were reenrolled nearly a decade
after the initial detection. Redetection of HPV 16 occurred in 11
(40.7%) of these women. Were these new HPV 16 infections or a re-
detection of a low-level persistent infection? This is a diﬃcult if not
impossible question to answer, but a nearly identical LCR sequence of
earlier and later isolates occurred in most cases in which careful se-
quencing was performed. Such an identical sequence of the highly
variable LCR in isolates taken over longer time periods suggests that
either 1) the HPV 16 detected at the later time is actually the same as
the original one, and never actually cleared, or 2) the woman has been
re-infected with an identical HPV 16 isolate. Based on current beliefs
that type-speciﬁc HPV re-infections are uncommon, it is most likely that
these apparently “cleared” HPV 16 infections were actually infections
that persisted at low levels, as was previously suggested by shorter
studies of this same cohort of women [28]. Those that did appear to
“clear” their infection (as deﬁned by the study under the ﬁrst ob-
servation period) did have a longer interval between the last detection
and redetection from those that were censored in our study that was
statistically signiﬁcant. However, the purpose of the study was to in-
vestigate the redetection of HPV 16 and to demonstrate that the same
isolate could persist for many years. We do not have information as to
what occurred during the intervening period and HPV 16 could have
been present at low-levels during this time.
The issue of low-level persistence, or latency of HPV has been a
controversial issue. In the current study, most of the redetections of
HPV 16 were found in the ﬁrst visit where the sampling area included
the cervix as opposed to the second self-obtained swab. As shown in
Table 2, these redetections were associated with quantitatively low
viral loads (compared to those found in the initial HPV detection),
having a band intensity of 1 or 2, based on our semi-quantitative 1
through 5 scoring system as previously published [22]. These lower
viral loads may suggest local immune control by the host or viral in-
tegration. Interestingly, the HPV 16 redetection with the strongest band
intensity (Participant 11) was also the isolate that diﬀered the most
from the HPV 16 detected during the YWP study (that is, the highest
percentage of non-identities). This relatively high band intensity of HPV
16 associated with non-identity may be a clue to true reinfection with a
diﬀerent HPV 16 variant.
Animal models have suggested that papillomaviruses indeed can
exist in a latent state [29]. In a cottontail rabbit papillomavirus (CRPV)
model, persistence of viral DNA was seen in experimental inoculation of
the skin of the rabbit after the resolution of the papilloma that formed
in response to the initial inoculation. DNA at these sites was associated
with a lower viral copy number than was in the papilloma. However,
these areas were virologically competent, as the latent sites were cap-
able of forming papillomas with or without skin irritation [30]. Canine
oral papillomavirus (COPV) reactivation has also been shown when
immunosuppression is induced [31].
Few studies have investigated the persistence of HR-HPV types with
such long intervening periods of non-observation as in ourstudy, and
even fewer have utilized sequencing of HPV isolates in follow-up stu-
dies. Sycuro et al., [7] reenrolled a cohort of university-aged women
who had followed longitudinally for HPV infections. In their follow-up,
16.3% of these women had the same HR-HPV type redetected. Se-
quencing of the E6 gene revealed that some HPV 16 redetection events
were due to the same variant [7]. They also noted that redetection of
the same HPV type was positively associated with sporadic detection of
that type during their ﬁrst observation period, a ﬁnding that further
supports the notion that long-term persistent infections (with the same
HPV isolate) account for a signiﬁcant proportion of HPV DNA detection
later in life.
Human studies of HPV latency are limited by infrequent sampling,
reporting biases, and short periods of observation; thus the proportion
of new HPV detection resulting from recent sexual acquisition versus
reactivation of a prior infection is not known [13]. In spite of these
limitations, Kocjan et al., using partial and full-length genome se-
quencing, showed that recurrence of laryngeal papillomas caused by
HPV 6 or HPV 11 were likely due to the persistence of a single HPV
Table 4
Pap smear and HPV results from Visit 1.
Pap smear result HPV 16 Any HR-HPV HR-HPV
Positive Positive Negative
Normal pap (N = 23) 11 12 11
ASCUS (N = 2) 0 1 1
LGSIL (N = 2) 0 1 1
Table 5
Nucleotide sequencing of the LCR segment in redetected HPV 16 paired isolates.
Participant
Number
Number of
nucleotides
sequenced
Number of non-
identities
Percent
similaritya
1 744 13 98.3
2 745 1 99.9
5 747 5 99.3
7 748 13 98.3
10 752 3 99.6
11 744 15 98.0
a Calculated percent similarity: (# of nucleotides that are non-identities / total # of
nucleotides) multiplied by 100.
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variant obtained in the original isolate and subsequent specimens, 1–22
years later [32]. Recently, van der Weele, et al., successfully utilized a
Sanger-based method of whole genome sequencing to analyze persis-
tent variants of HPV 16. In this study, the majority of the isolates were
found to be identical during periods of repeated detection, with only
one reinfection having been detected. However, there were no inter-
vening periods of non-detection in this study [33]. Studies of women
during prolonged periods of sexual inactivity have detected new HPV
type-speciﬁc infections suggesting the possibility of reactivation
[34,35]. These studies represent the mounting evidence in support of an
HPV latent state.
There are several limitations to this study. First, only 27 women
were included in the analysis. These women were part of a larger cohort
(147 women) who were followed intensively for up to 8 years. Second,
not every HPV 16 isolate could be sequenced, possibly due to either a
very low abundance of DNA or due to degradation of DNA. Our se-
quencing results are suggestive of persistent isolates of HPV 16 in most
participants whose isolates could be sequenced, but this was limited to
a small, yet highly variable, region of the HPV genome. The application
of techniques such as next generation sequencing may be useful in fu-
ture studies to further clarify the true pathophysiology of episodic HPV
detection [36]. The use of next generation sequencing techniques is
relatively new in its application to the study of HPV persistence and
diﬀerent techniques may provide slightly diﬀerent results. The lack of
consensus as to what threshold of non-identities is considered to be a
diﬀerent isolate, especially in the setting of an infection that has po-
tentially persisted for nearly ten years and in a potentially altered cell
that may have reduced DNA proofreading capabilities, further hampers
the determination of an HPV latent state. Mutations in the human
genome are thought to accumulate in persistently infected cells in HPV
related cancers, and this may also be true in the HPV genome. As more
women are followed with serial HPV DNA tests, more opportunities to
answer this question will arise.
If HPV can exist in a latent state, then low-level persistence and
episodic detection may be lifelong phenomena. This is important for
two reasons: First, low-level persistence of HPV 16 would obviously
mean that the virus did not actually clear, and could eventually lead to
a dysplastic lesion in a woman's future, even if the infection is present at
times at levels below the detection limit of standard PCR assays.
Second, when a “new” infection is detected in a screening test of a
mature woman, this may in fact represent episodic detection of a low-
level persistent infection acquired many years before. As stated earlier,
understanding the trajectory of low-level persistent infection versus
infections that are newly acquired in mid-adult life becomes even more
imperative clinically.
In conclusion, these data support the low-level persistence and
episodic detection of HPV 16 even after many years after initial de-
tection. The clinical implications of these ﬁndings support the need of
early vaccination among adolescents. As traditional cytology screening
is replaced by primary HPV DNA testing, a better understanding of HPV
epidemiology is imperative when assessing a positive HPV test with
negative cytology or in women with a lack of recent sexual activity.
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